Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Expert commentary: The SPIRIT-H2H trial

print
PRINT
insite
SEARCH

Laura Coates discusses why the results of the SPIRIT-H2H trial are important for clinical practice (2:41).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

print
PRINT

Related content

15-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Ixekizumab tops adalimumab in head-to-head PsA trial

15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Researcher comment: The SPIRIT-H2H trial

20-08-2018 | Psoriatic arthritis | Feature | Article

Into the clinic: Ixekizumab for the treatment of PsA

20-08-2018 | Psoriatic arthritis | Feature | Article

At a glance: Data supporting the approval of ixekizumab for PsA
Image Credits